Product Overview

Empadiet 25 contains Empagliflozin, a selective Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor developed for the effective management of Type 2 Diabetes Mellitus. It helps improve glycemic control by reducing the reabsorption of glucose in the kidneys, allowing excess glucose to be eliminated through urine. In addition to lowering blood glucose levels, Empagliflozin has demonstrated cardiovascular and renal benefits in eligible patients, making it an important component of modern diabetes management.

Empadiet 25 is commonly prescribed alongside a healthy diet and regular physical activity and may be used as monotherapy or in combination with other oral antidiabetic medications or insulin. Its once-daily dosing provides convenient administration while supporting long-term treatment adherence and comprehensive diabetes care.

Manufactured under stringent pharmaceutical quality standards, Empadiet 25 delivers consistent efficacy, safety, and reliability, helping healthcare professionals effectively manage Type 2 Diabetes Mellitus and reduce the risk of diabetes-related complications.

How It Works

Empagliflozin selectively inhibits the Sodium-Glucose Co-Transporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption into the bloodstream. This increases urinary glucose excretion, thereby lowering blood glucose levels independently of insulin. In addition to improving glycemic control, Empagliflozin may support cardiovascular health, kidney function, and modest reductions in body weight and blood pressure in appropriate patients.

Therapeutic Applications

Empadiet 25 may be prescribed for the management of:

• Type 2 Diabetes Mellitus
• Blood Glucose Control
• Heart Failure (in appropriate patients)
• Chronic Kidney Disease (CKD) in eligible patients
• Cardiovascular Risk Reduction
• Combination Therapy with other antidiabetic medications

Key Benefits

• Effectively lowers blood glucose levels.
• Once-daily oral therapy for improved patient convenience.
• Promotes urinary glucose excretion independent of insulin.
• Supports cardiovascular and renal health in appropriate patients.
• May contribute to modest weight and blood pressure reduction.
• Manufactured under stringent pharmaceutical quality standards.

Quality Commitment

Vinix Biopharma is committed to delivering high-quality antidiabetic medicines manufactured under stringent pharmaceutical quality standards. Empadiet 25 undergoes comprehensive quality assurance and rigorous testing to ensure safety, efficacy, consistency, and reliability. Every batch is carefully evaluated to maintain product integrity and support optimal patient care.

Storage Information

Store in a cool, dry place below 30°C. Protect from moisture and direct sunlight. Keep out of reach of children.

Disclaimer

Empadiet 25 should be used only under the supervision of a qualified healthcare professional. Dosage and duration of treatment should be determined by the treating physician based on the patient’s clinical condition, medical history, and therapeutic requirements.